Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCC1 | P33527 | 1/20 | 0.38 |
| ▸ | ABCC2 | Q92887 | 1/20 | 0.38 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CTSB | P07858 | 2/20 | 0.37 |
| ▸ | PPP3CB | P16298 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | TACR3 | P29371 | 6/20 | 0.34 |
| ▸ | CALCRL | Q16602 | 1/20 | 0.34 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | NQO2 | P16083 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7945558 | 0.90 | MCL1 (0.40) | ABCC1ABCC2ABCG2CYP3A4CTSB | |
| SCHEMBL5693290 | 0.87 | ABCC1 (0.38) | ABCC1ABCC2ABCG2CYP3A4CTSB | |
| SCHEMBL5692638 | 0.87 | MCL1 (0.40) | CYP3A4CTSBKDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL5692554 | 0.87 | KDM4E (0.39) | ABCC1ABCC2ABCG2CYP3A4CTSB | |
| SCHEMBL5693275 | 0.87 | CYP3A4 (0.44) | ABCC1ABCC2ABCG2CYP3A4CTSB | |
| SCHEMBL5693312 | 0.86 | KDM4E (0.42) | CTSBKDM4EALDH1A1SMN1; SMN2TACR3 | |
| SCHEMBL14307115 | 0.85 | MCL1 (0.40) | ABCC1ABCC2ABCG2CYP3A4CTSB | |
| SCHEMBL5692743 | 0.85 | MCL1 (0.40) | ABCC1ABCC2ABCG2CYP3A4CTSB | |
| SCHEMBL5692649 | 0.83 | CYP3A4 (0.44) | ABCC1ABCC2ABCG2CYP3A4CTSB | |
| SCHEMBL14282973 | 0.82 | KDM4E (0.40) | ABCC1ABCC2ABCG2CTSBKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1337550-B1 | HEPATITIS C TRIPEPTIDE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2006-05-24 | — | — | EP | disclosed |
| US-6872805-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-03-29 | — | — | US | disclosed |
| US-20020111313-A1 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2002-08-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020111313-A1 | Hepatitis C virus inhibitors | HAVCR2, ZC3HAV1, VIP | ABCC1 1256/4885ABCC2 3379/4885ABCG2 3761/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.